Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Jonathan E. Kolitz"'
Publikováno v:
Journal of Clinical Oncology. 40:e18594-e18594
e18594 Background: Disparities in cancer clinical trials limit the real-world reproducibility of their results while remaining inapplicable to excluded patients (pts) like those living with chronic viral infections. Non-Hodgkin lymphoma (NHL) has an
Autor:
Stephen A. Strickland, Jonathan E. Kolitz, Gary J. Schiller, Donna E. Hogge, Robert K. Stuart, Stefan Faderl, Laura F. Newell, Jorge E. Cortes, Tara L. Lin, Daniel H. Ryan, Jeffrey E. Lancet, Matthew J. Wieduwilt, Scott R. Solomon, Ellen K. Ritchie, Geoffrey L. Uy, Dale L. Bixby, Yu-Lin Chang
Publikováno v:
Journal of Clinical Oncology. 38:7510-7510
7510 Background: CPX-351 (Vyxeos; daunorubicin and cytarabine liposome for injection), a dual-drug liposomal encapsulation of cytarabine [C] and daunorubicin [D], is approved by the FDA and EMA for the treatment of adults with newly diagnosed therapy
Autor:
Stephen Marcus, Robert K. Stuart, Jonathan E. Kolitz, Matthew J. Wieduwilt, Don A. Stevens, Tibor Kovacsovics, Michael B. Maris, John L. Reagan, Paul J. Shami, Cecilia Arana-Yi, Moshe Yair Levy, Hana Safah, Michaela L. Tsai, Rachel J. Cook, Jay Yang, William B. Donnellan, Peter Westervelt
Publikováno v:
Journal of Clinical Oncology. 37:7001-7001
7001 Background: Elderly AML patients have poor outcomes irrespective of therapy. CX-01 is a low anticoagulant heparin derivative that retains heparin’s ability to alter the activity of the CXCL12/CXCR4 axis, P-selectin, extracellular histones, and
Autor:
Philip C. Amrein, William Blum, Peter M. Voorhees, Daniel J. DeAngelo, Martha Wadleigh, Eyal C. Attar, Richard Stone, Clara D. Bloomfield, Jonathan E. Kolitz, Bayard L. Powell, Guido Marcucci, Jeffrey L. Johnson, Richard A. Larson, Barry K. Moser, Gerard Lozanski, Eunice S. Wang
Publikováno v:
Journal of Clinical Oncology. 31:923-929
Purpose The purpose of this study was to determine remission induction frequency when bortezomib was combined with daunorubicin and cytarabine in previously untreated older adults with acute myeloid leukemia (AML) and safety of bortezomib in combinat
Autor:
John C. Byrd, Jennifer A. Woyach, Jonathan E. Kolitz, Kanti R. Rai, Vicki A. Morrison, Martin S. Tallman, Amy S. Ruppert, Thomas S. Lin, Richard A. Larson, Susan Geyer, Andrew Belch, Frederick R. Appelbaum
Publikováno v:
Journal of Clinical Oncology. 31:440-447
Purpose Chronic lymphocytic leukemia (CLL) is a disease of the elderly, yet few clinical trials include a significant number of older patients, and outcomes after specific therapies can be different depending on age. Patients and Methods We examined
Autor:
Michael D. Radmacher, Sebastian Schwind, Kati Maharry, Susan P. Whitman, Klaus H. Metzeler, Joseph O. Moore, Richard A. Larson, Deedra Nicolet, Meir Wetzler, Andrew J. Carroll, Heiko Becker, Krzysztof Mrózek, Jihane Khalife, Michael A. Caligiuri, Jessica Kohlschmidt, Maria R. Baer, Jonathan E. Kolitz, Bayard L. Powell, Guido Marcucci, Jason H. Mendler, Thomas H. Carter, Clara D. Bloomfield
Publikováno v:
Journal of Clinical Oncology. 30:3109-3118
Purpose To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures. Patients and Methods Youn
Autor:
Meir Wetzler, John Curfman, Michael A. Caligiuri, Heiko Becker, Sebastian Schwind, Klaus H. Metzeler, Joseph O. Moore, Dean Margeson, Richard A. Larson, Kati Maharry, Susan P. Whitman, Thomas H. Carter, Maria R. Baer, William Blum, Andrew J. Carroll, Yue-Zhong Wu, Jonathan E. Kolitz, Bayard L. Powell, Kelsi B. Holland, Clara D. Bloomfield, Michael D. Radmacher, Krzysztof Mrózek, Guido Marcucci
Publikováno v:
Journal of Clinical Oncology. 29:1373-1381
Purpose To determine the frequency of TET2 mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene- and microRNA-expression signatures in patients with primary cytogenetically normal acute myeloi
Autor:
Christine E. Swenson, Lawrence D. Mayer, Alan F. List, Steven L. Allen, Jeffrey E. Lancet, Arthur C. Louie, Eric J. Feldman, Ekatherine Asatiani, Ellen K. Ritchie, Jonathan E. Kolitz, Gail J. Roboz
Publikováno v:
Journal of Clinical Oncology. 29:979-985
Purpose This phase I dose-escalation trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities, and pharmacokinetics of CPX-351. Patients and Methods CPX-351 induction was administered on days 1, 3, and 5 by 90-minute infu
Autor:
Kati Maharry, Michael D. Radmacher, Claudia D. Baldus, Kelsi B. Holland, Krzysztof Mrózek, Klaus H. Metzeler, Richard A. Larson, Heiko Becker, Peter Paschka, Andrew J. Carroll, Sebastian Schwind, Dean Margeson, Christopher Hickey, Bayard L. Powell, Susan P. Whitman, Clara D. Bloomfield, Jonathan E. Kolitz, Michael A. Caligiuri, Ramiro Garzon, Guido Marcucci, Shujun Liu
Publikováno v:
Journal of Clinical Oncology. 28:5257-5264
Purpose To evaluate the prognostic significance of expression levels of a single microRNA, miR-181a, in the context of established molecular markers in cytogenetically normal acute myeloid leukemia (CN-AML), and to gain insight into the leukemogenic
Autor:
Stephen A. Strickland, Michael Chiarella, Daniel H. Ryan, Robert K. Stuart, Gary J. Schiller, Matthew J. Wieduwilt, Jorge E. Cortes, Bruno C. Medeiros, Jeffrey E. Lancet, Tara L. Lin, Donna E. Hogge, Richard Stone, Arthur C. Louie, Laura F. Newell, Geoffrey L. Uy, Jonathan E. Kolitz, Dale L. Bixby, Robert J. Ryan, Scott R. Solomon, Ellen K. Ritchie
Publikováno v:
Journal of Clinical Oncology. 36:7040-7040
7040Background: CPX-351, a liposomal encapsulation of cytarabine (C) and daunorubicin (D) at a synergistic ratio, is approved in the US for treatment of adults with newly diagnosed therapy-related ...